COVID-19 causes pharmacodynamic changes, such as the interaction between dopaminergic and renin-angiotensin systems in the striatum and systemic inflammation responses in PD patients, leading to the worsening of PD and exacerbation of symptoms. This evidence concerns the gene REN and Parkinson disease.